- Home
- KWE vs LIXT Comparison
KWE vs LIXT Comparison
Compare KWE & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWE
- LIXT
- Stock Information
- Founded
- KWE 2017
- LIXT 2005
- Country
- KWE Canada
- LIXT United States
- Employees
- KWE N/A
- LIXT N/A
- Industry
- KWE
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- KWE
- LIXT Health Care
- Exchange
- KWE Nasdaq
- LIXT Nasdaq
- Market Cap
- KWE 3.1M
- LIXT 3.0M
- IPO Year
- KWE N/A
- LIXT N/A
- Fundamental
- Price
- KWE $10.76
- LIXT $0.74
- Analyst Decision
- KWE
- LIXT
- Analyst Count
- KWE 0
- LIXT 0
- Target Price
- KWE N/A
- LIXT N/A
- AVG Volume (30 Days)
- KWE 3.0M
- LIXT 82.2K
- Earning Date
- KWE 08-15-2025
- LIXT 08-07-2025
- Dividend Yield
- KWE N/A
- LIXT N/A
- EPS Growth
- KWE N/A
- LIXT N/A
- EPS
- KWE N/A
- LIXT N/A
- Revenue
- KWE $2,115,849.00
- LIXT N/A
- Revenue This Year
- KWE N/A
- LIXT N/A
- Revenue Next Year
- KWE N/A
- LIXT N/A
- P/E Ratio
- KWE N/A
- LIXT N/A
- Revenue Growth
- KWE 121.88
- LIXT N/A
- 52 Week Low
- KWE $3.86
- LIXT $0.64
- 52 Week High
- KWE $116.99
- LIXT $3.00
- Technical
- Relative Strength Index (RSI)
- KWE 63.32
- LIXT 30.79
- Support Level
- KWE $7.16
- LIXT $0.64
- Resistance Level
- KWE $15.37
- LIXT $0.93
- Average True Range (ATR)
- KWE 1.94
- LIXT 0.13
- MACD
- KWE 0.32
- LIXT -0.05
- Stochastic Oscillator
- KWE 55.72
- LIXT 16.99
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.